Drug intelligence / Profile preview

XLS-203

Development stage: Preclinical
Lead developer: Xiangxue Precision Medical Technology
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

XLS-203 is an investigational T-cell receptor engineered T-cell (TCR-T) therapy developed by Guangdong Xiangxue Precision Medical Technology (XLifeSc). The therapy consists of autologous T cells that are genetically modified to express a specific T-cell receptor (TCR) targeting the KRAS G12V neoantigen peptide presented by the HLA-A*11:01 molecule. By specifically recognizing this oncogenic driver mutation, XLS-203 is designed to selectively identify and eliminate tumor cells harboring the KRAS G12V mutation while sparing healthy tissue. It is currently in preclinical development for the treatment of colorectal cancer.

Targets

KRASG12V (KRAS G12V)pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on XLS-203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XLS-203.

Explore the full profile